Aims
To determine the risk of venous thromboembolism (VTE) defined as the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients with psoriatic arthritis (PsA), psoriasis and rheumatoid arthritis (RA) compared with population controls.
..

Methods and results
A cohort study was conducted in a primary care medical record database in the UK with data from 1994-2014 among patients with PsA, RA, or psoriasis. Cox proportional hazards models were used to calculate the relative hazards for DVT, PE, and VTE. An interaction with disease modifying anti-rheumatic drugs (DMARD) was hypothesized a priori and was significant. Patients with PsA (n = 12 084), RA (n = 51 762), psoriasis (n = 194 288) and controls (n = 1 225 571) matched on general practice and start date were identified. Patients with RA (with and without a DMARD prescription) and patients with mild psoriasis had significantly elevated risks of VTE (HR 1.35, 1.29 , and 1.07, respectively) after adjusting for traditional risk factors. Severe psoriasis and PsA prescribed a DMARD had an elevated but not statistically significant risk for VTE. Findings were similar for DVT. The age-and-sex-adjusted risk of PE was elevated in RA, severe psoriasis and PsA patients prescribed a DMARD.
.. Conclusion
While systemic inflammation is a risk factor for VTE, the risk of VTE compared with controls is different among patients with three different inflammatory disorders: RA, PsA, and psoriasis. 
Introduction
Venous thromboembolism (VTE) is a relatively common and potentially fatal condition with an incidence of three cases per 1000 patient years. [1] [2] [3] A number of risk factors for VTE, which includes both deep vein thrombosis (DVT) and pulmonary embolus (PE), have been identified. One such potential risk factor for VTE is systemic inflammation. [4] [5] [6] This association is biologically plausible given the effects of systemic inflammation on platelet aggregation, coagulation cascade activation, stimulation of pro-coagulant activity of peripheral blood monocytes, endothelial damage, and potentially changes in blood flow. 4, 7 Previous studies have suggested an increased risk of VTE among patients with elevated serum c-reactive protein (CRP), interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1 and tumor necrosis factor (TNF). 4 However, it is unclear whether inflammation and the resulting cytokines are causal factors in the development of VTE. Psoriasis, psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are chronic inflammatory diseases. These disorders result in activation of both the Th1 and Th17 inflammatory pathways resulting in increased IL-6 and TNF and patients often have an elevated CRP. Chronic systemic inflammation in these disorders may result in accelerated atherosclerosis in patients with psoriasis, PsA and RA. [8] [9] [10] However, less is known about whether these disorders are associated with VTE. A handful of studies have examined the risk of VTE in patients with RA and psoriasis. 6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In a study by Kim et al in 2013, patients with RA had a 40% increase in VTE compared with patients without RA after adjustment for other known risk factors. 13 Previous studies performed in psoriasis were highly heterogeneous and many did not optimally adjust for additional risk factors for VTE. To our knowledge, there are no studies to date examining the risk of VTE in PsA. If patients with these disorders have an increased risk of VTE, improved prevention and monitoring could improve morbidity and mortality from VTE in these patients.
We performed a population-based cohort study to examine whether psoriasis, PsA and RA are associated with an increased risk of VTE after adjustment for established risk factors for VTE. We hypothesized that all three inflammatory diseases are associated with increased risk of VTE (including PE and DVT) as compared with unexposed patients without these diseases.
Methods
Study Design: We performed a cohort study to examine the risk of incident VTE among patients with psoriasis, PsA, and RA.
Data Source: Data from The Health Improvement Network (THIN) in the United Kingdom (UK) between 1994 and January 2014 was used. THIN is representative of the UK population in terms of age, sex, geography, and medical conditions. 22 Study Population: All patients with PsA, psoriasis or RA between the ages of 18 and 89 at the start date were included if they had observation time in THIN after Vision software implementation. Patients were excluded if they died or transferred out of the practice prior to the implementation of Vision software. Up to 5 unexposed controls were randomly selected for each patient with psoriasis, PsA and RA and were matched on practice and start date within the practice (defined as the latest of diagnosis date or 180 days after registration date). Matching is described in more detail in the Supplementary material online, Methods.
Exposure Definitions: PsA, psoriasis, and RA were defined by the presence of at least one READ code consistent with these diseases. 23 READ codes for psoriasis, PsA, and RA have been previously validated within the same or analogous large medical record databases. [24] [25] [26] [27] Some patients may have been diagnosed with two of the conditions (e.g. psoriasis and PsA). These patients were included in both cohorts (and had separate matched controls based on their start dates). In a sensitivity analysis, we examined alternative definitions of disease groups including restricting the group of patients with psoriasis to patients without a code for RA or PsA.
Outcome Definition: The outcomes of interest are VTE, PE, and DVT. The primary outcome was VTE, the combined endpoint of PE and DVT. The individual diagnoses (DVT and PE) were the secondary outcomes. Codes for VTE have been previously validated within the general practitioners research database (GPRD), a similar database to THIN. 28 Covariates of Interest: All covariates of interest were measured prior to and including the index date. The potential confounders measured are listed in the see Supplementary material online, Methods. A priori we hypothesized a statistical interaction between disease status and disease modifying anti-rheumatic drugs (DMARD) use.
Person time calculation: The index date was the latest of diagnosis of psoriasis, PsA, or RA (diagnosis date for unexposed controls, as noted above, was the visit date within 6 months of the matched patient's diagnosis date), start of therapy for those in the DMARD groups, 180 days after registration in the practice, and Vision software implementation date. Cohort time ended at earliest of development of the outcome of interest, transfer out of the practice, the date the practice stopped contributing to THIN, death, or the end of the study period.
Statistical Analysis: Statistical analyses were performed using STATA 13.0 (College Station, TX). Demographics and covariate distribution among the study groups were descriptively reported. The cumulative incidence of VTE was descriptively reported as the number of new events divided by the number of person years per group. Cox proportional hazards models were used to estimate the unadjusted and age-and-sex adjusted hazard ratios (HR) with 95% confidence intervals (CI). We next fit models that adjusted for additional covariates using a purposeful selection modelling approach. 29 Covariates with biologically plausible relationships with the exposure and outcome or that had a P-value of <0.05 in the univariable model were added to create a full model. Covariates were then removed one at a time based on P-value and maintained in the model if P < 0.1 and removal resulted in a change in the point estimates of the main effects by >10-15%. The same modelling procedure was used for DVT and PE as secondary outcomes. Sensitivity analyses are described in the Supplementary material online, Methods.
Results
Patients with PsA (n = 12 084), RA (n = 51 762), and psoriasis (n = 194 288) were identified and matched to 1 225 571 controls. Among these groups, 53 and 61% of patients with PsA and RA Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis
respectively received a DMARD and 5.6% of patients with psoriasis received either phototherapy or a systemic therapy for psoriasis. Baseline characteristics are reported in Table 1 . Rheumatoid arthritis patients were older and nearly 70% were female as opposed to the other three groups in which mean age was around 50 years and approximately half were female. Comorbidities (unadjusted for age and sex) were in general more common in RA patients although BMI was numerically greater in patients with PsA and severe psoriasis. Additional baseline demographics are provided in see Supplementary material online, Table S1 .
Approximately 2% of patients developed a DVT and 0.5% developed a PE during the mean follow up period of 6.3 years. The unadjusted incidence of VTE (combined), DVT, and PE ( Table 2) were highest in patients with RA and similar in patients with severe psoriasis and PsA. Incidence declined over time among the unexposed (see Supplementary material online, Table S2 ). The unadjusted, age-and sex-adjusted and fully adjusted Cox proportional hazards models are presented in Table 3 . The age-and sex-adjusted model for VTE suggested a significantly elevated risk for all disease groups. After adjusting for age, sex, and other known risk factors for VTE, patients with RA had the highest risk of VTE overall (No DMARD HR 1.29 Tables S3-S5) . However, when age was used as a time scale, the HR for PsA increased to 1.30 (95%CI: 1.08-1.57) and 1.47 (95%CI: 1.23-1.75) for patients without and with a DMARD prescription respectively. Similarly, the HR for mild psoriasis increased to 1.18 (1.13-1.22).
Discussion
Venous thromboembolism is a relatively common condition that may result in significant morbidity and mortality. In this populationbased cohort study, patients with PsA, RA, and psoriasis had an elevated incidence of VTE compared with patients without these common inflammatory disorders after adjusting for age and sex. The age-and sex-adjusted risk for PE was significantly elevated compared with controls except for patients with mild psoriasis. Patients with RA prescribed a DMARD and severe psoriasis had higher point estimates for the outcomes of interest than those without a DMARD prescription suggesting level of systemic inflammation may play a role. Furthermore, our data suggest that RA and mild psoriasis are independent risk factors for VTE after adjusting for other known risk factors for VTE. Comparison among these diseases is important for understanding how these diseases are similar and different, particularly in terms of burden and consequences of systemic inflammation. 30 To our knowledge this is the first study to evaluate the risk of VTE in PsA. The age-and sex-adjusted HR for PE among patients with PsA were significantly increased but this was not statistically significant after adjusting for other known risk factors. This was possibly related to the small number of events and insufficient power to detect The fully adjusted models include age, sex, history of cancer, hypertension, hospitalization in the baseline period, joint replacement in the baseline period, liver disease, oral glucocorticoids, NSAIDs, COPD, drinking and smoking in the baseline period.
Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis a difference between patients with and without PsA. (When all patients with PsA were pooled, the fully adjusted HR for PE was 1. Thus, our study is the first study of psoriasis patients, both men and women, to examine the risk for VTE compared with internal controls after accounting for established risk factors for VTE. Previous studies have found an increased risk of VTE in RA, including one from a similar population in THIN. 15, 16 Choi et al. examined the risk of VTE among patients with RA in THIN using an incident disease cohort of patients with RA prescribed a DMARD (similar to our RA-DMARD group). In addition to the use of an incidence cohort, other differences include defining VTE as a medical code for VTE plus a prescription for an anticoagulant and dates of inclusion were slightly different (1986-2010 compared with 1994-2014 in our study). The HR for both PE (1.74 vs. 2.16 ) and VTE were attenuated in our study (1.35 compared to 2.14). In Choi et al., the risk was highest in the one year after RA diagnosis and then steadily declined. We used a prevalence cohort in our study. While we didn't find significantly different results when we examined the incident cohort by the same definition as Choi et al., the examination of all time (rather than just the first year) may have decreased the HR overall. On the other hand, our results were strikingly similar to results published by Kim et al. who examined the risk or VTE among patients with RA in an administrative database (HR 1.4 ; 95% CI 1.1-1.7). 13 In this sense, the inclusion of patients with RA served as an internal positive control and provides face validity for the remainder of the results. Additionally, Kim et al. examined the effect of prescriptions for DMARDs on the risk for VTE and found that patients initiating a TNF inhibitor had a higher risk for VTE compared with those prescribed a non-biologic DMARD (e.g. methotrexate) but this was only significant in the first time window after prescribing. Similar to Choi et al., this analysis likely reflects the high systemic inflammation in incident disease. As inflammation decreases, so too does the risk for VTE. 33 We were unable to repeat similar analyses as biologic DMARDs are prescribed by consultants in the UK and are thus not uniformly available in THIN.
Virchow used the triad of vascular injury, hypercoagulation, and venous stasis to describe the basic mechanisms leading to thrombosis. Systemic inflammation may affect at least two of three of these components. Upregulation of endothelial adhesion molecules and infiltration of activated inflammatory monocytes has been observed in the arterial walls of patients with systemic lupus erythematosus suggesting early vascular damage as a result of systemic inflammation. 7 Inflammation also has a direct impact on the coagulation cascade; thrombogenic factors upregulated by inflammation lead to hypercoagulation 34 and systemic inflammation, such as the inflammation seen in PsA, RA, and psoriasis, may lead to platelet aggregation and clot formation (see conceptual model in Figure 1) . 35 Previous studies have also found increased circulating microparticles from endothelial cells and platelets in patients with psoriasis 36 which may contribute to increased cardiovascular risk and potentially VTE as well. Overall, in the present study, the HR for VTE were lower in magnitude than the risk for major cardiovascular adverse cardiovascular events found in a previous study within the same cohort. 8 Additionally, this risk may be less than the risk conferred by Factor V Leiden, a prevalent thrombophilic condition present in 3-5% of the population, although this has not been examined. Beyond inflammation, other potential risk factors for VTE include obesity, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid use. [37] [38] [39] [40] Patients with psoriasis and PsA have been found to be more obese than the general population and patients with RA and PsA more frequently use NSAIDs and corticosteroids. While each was associated with VTE in the multivariable models, there was not a statistically significant interaction with any one of these risk factors in our study (data not shown). However, in the multivariable models including NSAIDs as a covariate, NSAIDs were independently associated with VTE (HR 1.33, data not shown). This has previously been described but warrants future study as the majority of patients in this population use these medications. 37 Strengths of this study include the use of a large population-based medical record database, broadly representative of the UK general population, the relatively large number of patients with PsA, psoriasis and RA, validation of the codes for the exposures and outcomes, and an unexposed cohort sampled from the general population. Additionally, the incidence rate for VTE found in our control population is nearly identical to reports from previous studies as noted in Table 2 (30/10 000 PYs in the UK, 38/10 000 PYs in our unexposed control population). 1 Limitations of the study include the risk of exposure misclassification (e.g. patients diagnosed with PsA may in reality have psoriasis and osteoarthritis). However, previous validation studies for PsA, RA, and psoriasis found high positive predictive values for the codes (85-95%) using GP confirmation. 24 
significantly elevated after adjustment for established VTE risk factors in RA and mild psoriasis. Our article has advantages over the previous analyses including comparison among three inflammatory diseases, identification and analysis of PsA as separate from severe psoriasis, and a more generalizable approach relevant for all patients with psoriasis, PsA, or RA. Thus, patients with one of these diseases and another risk factor for VTE such as general surgery, major trauma, immobility or oral contraceptives may warrant additional monitoring, and clinicians may counsel such patients on the use of compression stockings or consider VTE prophylaxis. Finally, clinicians should be aware of the increased risk of VTE and consider the diagnosis of PE or DVT in patients presenting with acute shortness of breath or acute lower extremity swelling.
Supplementary material
Supplementary material is available at European Heart Journal online. Figure 1 Conceptual model. We hypothesized that psoriasis, psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are associated with venous thromboembolism (VTE) as a result of local and/or systemic inflammation which then triggers prothrombotic pathways. Additional risk factors for VTE are also shown and were adjusted for in our analyses; they may be directly related to the risk for VTE or may act as confounders. In this model, we hypothesize local and/or systemic inflammation is a mediator or on the causal pathway between psoriasis or inflammatory arthritis and VTE. This hypothesis was not tested in this study. NSAID, non-steroidal anti-inflammatory drugs; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.
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